NICE appraisal and other related document
NHSScotland should note that:
1. Recommendations of NICE Single Technology Assessments (STAs) have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the SMC advice.
The Scottish Medicines Consortium (SMC) published a Statement of Advice on this medication for this indication in March 2009. In the absence of a submission from the holder of the marketing authorisation, this stated:
Cetuximab (Erbitux) is not recommended for use within NHSScotland for the treatment of
- patients with squamous cell cancer of the head and neck in combination with platinum based
- chemotherapy for recurrent and/or metastatic disease.
Click here for the advice of the Scottish Medicines Consortium
3. The opportunity is available to the manufacturer to make a submission to SMC for this product in this indication at any time.
If you need further assistance, please contact Eleanor Brownlee in the first instance, telephone 0141 225 6873.
